Skip to content
Peptigraph home

Semaglutide for Cognition: What the Evidence Shows

What human and animal studies show about Semaglutide for cognition, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
3
with an outcome for cognition, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for cognition, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
3
with an outcome for cognition

Evidence for cognition

Each row is an outcome related to cognition from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide for cognition: outcomes in published studies
OutcomeResultStudy typeSource
Clinical Dementia Rating-Sum of BoxesOral semaglutide did not slow clinical progression in early Alzheimer disease; both trials were discontinued for negative outcome.Human RCTn = 3808Lancet 2026, PMID 41865758
CDR-SB change from baselineCDR-SB score worsened by 2·3 and 2·2 with semaglutide vs 2·3 and 2·1 with placebo in the two trials.Human RCTn = 3808Lancet 2026, PMID 41865758
Cognitive deficit and dementiaSemaglutide was associated with lower risk of cognitive deficit (hazard ratio 0.72 vs sitagliptin and glipizide) and dementia (0.52 vs sitagliptin); observational association only.Human observationalEClinicalMedicine 2024, PMID 39764175
First-time Alzheimer disease diagnosisSemaglutide was associated with lower risk of a first Alzheimer diagnosis (hazard ratio 0.33 vs insulin, 0.59 vs other GLP-1 drugs); observational association only.Human observationaln = 1094761Alzheimer's & dementia 2024, PMID 39445596

Semaglutide and cognition are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our evidence scale.

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4Lancet 2026, PMID 41865758

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Other peptides people research for cognition

Tirzepatide

Common questions

Does Semaglutide help with cognition?

The strongest study we summarise for cognition is human rct evidence, across 3 studies with an outcome for cognition. A trial result is not an approval; see the legal status.

Is Semaglutide approved for cognition?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.

More on Semaglutide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  2. 212-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.EClinicalMedicine · 2024PMID 39764175Accessed 2 Oct 2026
  3. 3Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024PMID 39445596Accessed 2 Oct 2026

Found an error? Report a correction.